Literature DB >> 22471906

Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults.

Chonlaphat Sukasem1, Tim R Cressey, Pattamawan Prapaithong, Yardpiroon Tawon, Ekawat Pasomsub, Chutatip Srichunrusami, Thawinee Jantararoungtong, Marc Lallement, Wasun Chantratita.   

Abstract

AIMS: To investigate the frequency of CYP2B6 polymorphisms and the influence of haplotype structure on plasma efavirenz concentrations in Thai adults with HIV-1 infection.
METHODS: Genotyping of nine single nucleotide polymorphisms (SNPs, c.64C>T, c.499C>G, c.516G>T, c.785A>G, c.1375A>G, c.1459C>T, g.3003T>C, g.18492C>T and g.21563C>T) of CYP2B6 were performed using real-time PCR-based allelic discrimination on blood samples from 52 HIV-infected adults who had received an efavirenz-based regimen. Plasma efavirenz concentrations were measured by high performance liquid chromatography.
RESULTS: The minor allele frequencies for c.64C>T, c.516G>T, c.785A>G, g.3003C>T, g.18492T>C and g.21563C>T were 0.087, 0.365, 0.413, 0.308 and 0.356, respectively. However, no variant alleles were identified for three SNPs (c.499 C>G, c.1375 A>G and c.1459 C>T). Efavirenz plasma concentrations were significantly associated with c.516G>T (P= 0.0095), c.785A>G (P= 0.0017), g.21563C>T (P= 0.0036) and g.18492C>T (P= 0.0011). The composite CYP2B6 of three SNPs (c.516G ≥ T, c.785A ≥ G and g.21563C ≥ T) genotypes were significantly associated with higher efavirenz concentrations.
CONCLUSIONS: Our data indicate that the GAC-CYP2B6 haplotype is associated with higher plasma efavirenz concentrations in HIV-infected Thai adults.
© 2012 The Authors. British Journal of Clinical Pharmacology © 2012 The British Pharmacological Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22471906      PMCID: PMC3522814          DOI: 10.1111/j.1365-2125.2012.04288.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  28 in total

1.  The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity.

Authors:  Bryan A Ward; J Christopher Gorski; David R Jones; Stephen D Hall; David A Flockhart; Zeruesenay Desta
Journal:  J Pharmacol Exp Ther       Date:  2003-04-03       Impact factor: 4.030

2.  Efavirenz plasma concentrations and cytochrome 2B6 polymorphisms.

Authors:  Tristan Lindfelt; John O'Brien; Jessica C Song; Rajul Patel; Dean L Winslow
Journal:  Ann Pharmacother       Date:  2010-09-14       Impact factor: 3.154

3.  Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver.

Authors:  T Lang; K Klein; J Fischer; A K Nüssler; P Neuhaus; U Hofmann; M Eichelbaum; M Schwab; U M Zanger
Journal:  Pharmacogenetics       Date:  2001-07

4.  Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.

Authors:  C Marzolini; A Telenti; L A Decosterd; G Greub; J Biollaz; T Buclin
Journal:  AIDS       Date:  2001-01-05       Impact factor: 4.177

5.  Haplotype structure of CYP2B6 and association with plasma efavirenz concentrations in a Chilean HIV cohort.

Authors:  Daniel F Carr; Charles J L la Porte; Munir Pirmohamed; Andrew Owen; Claudia P Cortes
Journal:  J Antimicrob Chemother       Date:  2010-07-17       Impact factor: 5.790

6.  Efavirenz plasma levels for the prediction of treatment failure in heavily pretreated HIV-1 infected patients.

Authors:  P Langmann; B Weissbrich; S Desch; T Väth; D Schirmer; M Zilly; H Klinker
Journal:  Eur J Med Res       Date:  2002-07-24       Impact factor: 2.175

7.  Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens.

Authors:  Kiyoto Tsuchiya; Hiroyuki Gatanaga; Natsuo Tachikawa; Katsuji Teruya; Yoshimi Kikuchi; Munehiro Yoshino; Takeshi Kuwahara; Takuma Shirasaka; Satoshi Kimura; Shinichi Oka
Journal:  Biochem Biophys Res Commun       Date:  2004-07-09       Impact factor: 3.575

8.  Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection.

Authors:  Chantal Csajka; Catia Marzolini; Karin Fattinger; Laurent A Décosterd; Jacques Fellay; Amalio Telenti; Jérôme Biollaz; Thierry Buclin
Journal:  Clin Pharmacol Ther       Date:  2003-01       Impact factor: 6.875

9.  Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects.

Authors:  Lars Ståhle; Lars Moberg; Jan-Olof Svensson; Anders Sönnerborg
Journal:  Ther Drug Monit       Date:  2004-06       Impact factor: 3.681

10.  Higher efavirenz plasma levels correlate with development of insomnia.

Authors:  M Núñez; D González de Requena; L Gallego; I Jiménez-Nácher; J González-Lahoz; V Soriano
Journal:  J Acquir Immune Defic Syndr       Date:  2001-12-01       Impact factor: 3.731

View more
  19 in total

Review 1.  Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.

Authors:  Andrea Calcagno; Jessica Cusato; Antonio D'Avolio; Stefano Bonora
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

2.  Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.

Authors:  Zeruesenay Desta; Roseann S Gammal; Li Gong; Michelle Whirl-Carrillo; Aditya H Gaur; Chonlaphat Sukasem; Jennifer Hockings; Alan Myers; Marelize Swart; Rachel F Tyndale; Collen Masimirembwa; Otito F Iwuchukwu; Sanika Chirwa; Jeffrey Lennox; Andrea Gaedigk; Teri E Klein; David W Haas
Journal:  Clin Pharmacol Ther       Date:  2019-07-05       Impact factor: 6.875

Review 3.  Pharmacogenetics and Precision Medicine Approaches for the Improvement of COVID-19 Therapies.

Authors:  Mohitosh Biswas; Nares Sawajan; Thanyada Rungrotmongkol; Kamonpan Sanachai; Maliheh Ershadian; Chonlaphat Sukasem
Journal:  Front Pharmacol       Date:  2022-02-18       Impact factor: 5.810

4.  Influence of CYP2B6 and CYP3A4 polymorphisms on the virologic and immunologic responses of patients treated with efavirenz-containing regimen.

Authors:  Yaya Kassogue; Brehima Diakite; Mamoudou Maiga; Oumar Kassogue; Issa Konate; Kadidiatou Tamboura; Fousseyni Diarra; Zoumana Diarra; Mahamadou Karamoko Sawadogo; Yaya Goita; Sidi Boula Sissoko; Adama Seydou Sissoko; Nouhoum Guirou; Hind Dehbi; Sellama Nadifi; Sekou Bah; Cheick Bougadari Traore; Bakarou Kamate; Sounkalo Dao; Guimogo Dolo
Journal:  Pharmacogenet Genomics       Date:  2022-06-22       Impact factor: 2.000

5.  Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients.

Authors:  Weerawat Manosuthi; Chonlaphat Sukasem; Aroon Lueangniyomkul; Wiroj Mankatitham; Supeda Thongyen; Samruay Nilkamhang; Sukanya Manosuthi; Somnuek Sungkanuparph
Journal:  Antimicrob Agents Chemother       Date:  2012-12-17       Impact factor: 5.191

6.  Low level of efavirenz in HIV-1-infected Thai adults is associated with the CYP2B6 polymorphism.

Authors:  C Sukasem; W Manosuthi; N Koomdee; S Santon; T Jantararoungtong; S Prommas; M Chamnanphol; A Puangpetch; S Sungkanuparph
Journal:  Infection       Date:  2013-11-30       Impact factor: 3.553

7.  CYP2B6 18492T->C polymorphism compromises efavirenz concentration in coinfected HIV and tuberculosis patients carrying CYP2B6 haplotype *1/*1.

Authors:  Weerawat Manosuthi; Chonlaphat Sukasem; Supeda Thongyen; Samruay Nilkamhang; Sukanya Manosuthi; Somnuek Sungkanuparph
Journal:  Antimicrob Agents Chemother       Date:  2014-02-03       Impact factor: 5.191

8.  Genome-Wide Pharmacogenomic Study on Methadone Maintenance Treatment Identifies SNP rs17180299 and Multiple Haplotypes on CYP2B6, SPON1, and GSG1L Associated with Plasma Concentrations of Methadone R- and S-enantiomers in Heroin-Dependent Patients.

Authors:  Hsin-Chou Yang; Shih-Kai Chu; Chieh-Liang Huang; Hsiang-Wei Kuo; Sheng-Chang Wang; Sheng-Wen Liu; Ing-Kang Ho; Yu-Li Liu
Journal:  PLoS Genet       Date:  2016-03-24       Impact factor: 5.917

9.  A pharmacogenomic prospective randomized controlled trial of CYP2B6 polymorphisms and efavirenz dose adjustment among HIV-infected Thai patients: a pilot study.

Authors:  Pansachee Damronglerd; Chonlaphat Sukasem; Wilawan Thipmontree; Apichaya Puangpetch; Sasisopin Kiertiburanakul
Journal:  Pharmgenomics Pers Med       Date:  2015-10-03

10.  The use of pharmacogenetics in clinical practice for the treatment of individuals with HIV infection in Thailand.

Authors:  Asalaysa Bushyakanist; Apichaya Puangpetch; Chonlaphat Sukasem; Sasisopin Kiertiburanakul
Journal:  Pharmgenomics Pers Med       Date:  2015-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.